BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) ranks among the top stocks available for under $20. On October 1, BioCryst Pharmaceuticals declared the successful finalization of the previously reported divestiture of its European ORLADEYO (berotralstat) operations to Neopharmed Gentili. The agreement is worth $250 million upfront, subject to typical purchase price adjustments, with an additional potential of up to $14 million in future milestones dependent on sales in Central and Eastern Europe.
This divestiture significantly enhances BioCryst’s operational margins, given that the European operations were nearly breakeven at a direct level. BioCryst will shift its focus to boosting ORLADEYO sales within the US market, while Neopharmed Gentili takes charge of commercialization throughout Europe, maintaining the European commercial team established by BioCryst for consistent operations.
Notably, despite the absence of European revenue post-transaction, BioCryst is on track to achieve the upper range of its 2025 revenue projections, estimated at $580 million to $600 million.
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) operates as a biotech firm, pioneering oral small-molecule and injectable protein therapeutics aimed at addressing rare diseases.
While recognizing the investment potential in BCRX, we argue that some AI stocks present greater upside potential alongside reduced downside risk. For those seeking an exceptionally undervalued AI stock poised to benefit from trends stemming from the Trump administration’s tariffs and the shift towards onshoring, check out our complimentary report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published at Insider Monkey.
